The field has been blessed in recent years with a host of new pharmacologic agents which have led to improved overall results. The optimal application of these agents is unknown. Multiple protocols exist. We are interested in studying factors which may lead to optimal selection of immunosuppressive agents for each patient. We are also developing a clinical tolerance strategy which involves the harvesting and infusion of donor specific stem cells after kidney transplantation.
Projects are available for summer research and year-long longitudindal study.